Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
Type:
Grant
Filed:
October 23, 2013
Date of Patent:
May 23, 2017
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: The disclosure relates to chemokine receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing chemokine related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
Type:
Application
Filed:
May 15, 2015
Publication date:
May 18, 2017
Applicant:
Emory University
Inventors:
Bryan D. Cox, Lawrence J. Wilson, Anthony Prosser, Dennis C. Liotta, James P. Snyder
Abstract: Methods, systems and computer-readable storage media relate to determining individualized treatment planning margins. The methods may include processing motion data of a target obtained from at least one marker for one or more periods. Each period may include a plurality of time intervals. The processing may include processing the motion data to determine an isocenter for each time interval along at least one of the axes of motion. The axes can include the x axis, the y axis, and/or the z axis. The method may include determining motion prediction data for each of the at least one of the axes; and determining treatment planning margins for each of the at least one of the axes based on the motion prediction data. The individualized treatment margins can be smaller and more optimal because the treatment margins can incorporate patient specific patterns of motion of a target (e.g., an organ).
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
May 16, 2017
Assignees:
Emory University, University of Tennessee Research Foundation
Inventors:
Mohammad Khurram Khan, Michael Edward Howard, Laurence F. Miller
Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.
Abstract: Disclosed are methods for diagnosing declarative memory loss using mouse tracking to follow the visual gaze of a subject taking a visual paired comparison test. Also disclosed are methods for diagnosing dementia such as mild cognitive impairment and Alzheimer's disease.
Type:
Grant
Filed:
February 26, 2010
Date of Patent:
April 25, 2017
Assignee:
Emory University
Inventors:
Yevgeny E. Agichtein, Elizabeth A. Buffalo, Dmitry Lagun, Cecelia Manzanares, Stuart Zola
Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersonmia; endozepine related recurrent stupor; and amphetamine resistant hypersonmia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.
Type:
Grant
Filed:
March 12, 2009
Date of Patent:
April 11, 2017
Assignee:
Emory University
Inventors:
Kathy P. Parker, David B. Rye, Andrew Jenkins
Abstract: This disclosure relates to diagnostic testing for subjects with or at risk of dementia and methods related thereto. In certain embodiments, the disclosure relates to methods of diagnosing a frontotemporal lobar degeneration subtype comprising measuring total Tau and Tau phosphorylated at threonine 181 in a sample from a subject, calculating a ratio of Tau phosphorylated at threonine 181 to total Tau, and making a diagnosis of the subtype based on said ratios. Typically, the sample is of cerebrospinal fluid and the frontotemporal lobar degeneration subtypes are selected from frontotemporal lobar degeneration with immunoreactive lesions to Tau and frontotemporal lobar degeneration with immunoreactive lesions to TAR DNA binding protein of 43 kD.
Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
Abstract: Methods, systems and computer-readable storage mediums relate to imaging techniques of a region, for example, the brain, with magnetization transfer contrast (MTC°) effects with less specific absorption rate (SAR). The methods, systems and computer-readable storage mediums may include acquiring MR image data from at least one magnetic resonance (MR) scan that includes a pre-pulse signal and a pulse sequence. The pre-pulse signal may be less than 500°, e.g., from about 150° to 425°, and the pulse-sequence may be a gradient echo based sequence. The methods, systems and computer-readable storage mediums may include generating information associated with an image of at least one region of a subject. The information may include quantitative or qualitative information of a region of a brain. The quantitative information may include volume information, contrast to noise ratio information, number of voxels, as well as other information.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
March 21, 2017
Assignee:
Emory University
Inventors:
Daniel E. Huddleston, Xiaoping P Hu, Sinyeob Ahn, Xiangchuan Chen
Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.
Type:
Grant
Filed:
November 27, 2009
Date of Patent:
March 21, 2017
Assignees:
Emory University, Dana-Farber Cancer Institute, Inc.
Abstract: In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of 5 treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof.
Abstract: This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: or salts, esters or prodrugs thereof as described herein.
Type:
Grant
Filed:
July 8, 2015
Date of Patent:
March 14, 2017
Assignees:
Emory University, Mercer University, Union University
Inventors:
Jack L. Arbiser, J. Philip Bowen, E. Blake Watkins
Abstract: This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.
Type:
Grant
Filed:
January 22, 2015
Date of Patent:
March 7, 2017
Assignees:
Emory University, Georgia Tech Research Corporation
Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
February 21, 2017
Assignee:
Emory University
Inventors:
Richard D. Cummings, Sean R. Stowell, Connie Arthur
Abstract: This disclosure relates to N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8 -(dimethylamino)naphthalen-1(4H)-ylidene)-N-methylmethanaminium, derivatives, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I. In certain embodiments, the disclosure relates to methods of treating or preventing Nox related diseases and conditions comprising administering an effective amount of compounds disclosed herein to a subject in need thereof. In certain embodiments, the Nox related disease or condition is cancer.
Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
Type:
Grant
Filed:
February 17, 2015
Date of Patent:
January 17, 2017
Assignee:
Emory University
Inventors:
Lawrence J. Wilson, John Wiseman, Dennis C. Liotta, Michael G. Natchus
Abstract: An apparatus includes a component having a shape memory material. The shape memory material has a first shape including a substantially elongate segment. The shape memory material has a second shape including a helix having a first ring and a second ring configured to exert a compressive force on a membrane interleaved between the first ring and the second ring and lying in a plane substantially perpendicular to an axis of the helix, the shape selectable based on an external stimulus.
Type:
Grant
Filed:
November 24, 2010
Date of Patent:
January 10, 2017
Assignees:
Emory University, Georgia Tech Research Corporation
Inventors:
Timothy W. Olsen, David W. Rosen, Shreyes N. Melkote, George K. Mathai
Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
Type:
Application
Filed:
August 19, 2016
Publication date:
January 5, 2017
Applicants:
Emory University, YOUR ENERGY SYSTEMS, LLC, Children's Healthcare of Atlanta, Inc.
Inventors:
Lou Ann Brown, Frederick Timothy Guilford
Abstract: Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid analogues and methods using the novel steroid analogues for the treatment and prevention of neurodegeneration in a patient following injury to the central nervous system.
Type:
Grant
Filed:
February 26, 2009
Date of Patent:
December 27, 2016
Assignee:
Emory University
Inventors:
Christopher Macnevin, Donald G. Stein, Dennis C. Liotta, Iqbal Sayeed, David B. Guthrie, Mark A. Lockwood, Michael G. Natchus
Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
Type:
Application
Filed:
June 27, 2014
Publication date:
December 22, 2016
Applicant:
Emory University
Inventors:
Jeff M. Sands, Mitsi A. Blount, Janet D. Klein